Newsoara Expands In-Licensed Territory for BET Inhibitor to Asia
November 15, 2021 at 06:21 AM EST
Newsoara Biopharma of Shanghai expanded its partnership with Zenith Epigenetics for a BET inhibitor to include Asia, India and ten Eurasian countries. In 2019, Newsoara acquired greater China rights to ZEN-3694 in a deal worth up to $78 million. In exchange for the expanded rights, Newsoara will pay $3.5 million upfront plus buy 1.5 million Zenith units for $1 each. Each unit consists of one share and a warrant to purchase one half of a share. Each full share will cost $1. Zenith is located in Calgary , Alberta . More details.... Share this with colleagues: // //